MENU
+Compare
KALV
Stock ticker: NASDAQ
AS OF
Jul 11, 04:59 PM (EDT)
Price
$14.53
Change
-$0.98 (-6.32%)
Capitalization
725.33M

KALV KalVista Pharmaceuticals Forecast, Technical & Fundamental Analysis

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases... Show more

KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for KALV with price predictions
Jul 10, 2025

KALV in -1.65% downward trend, falling for three consecutive days on June 30, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where KALV declined for three days, in of 302 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 3 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

KALV broke above its upper Bollinger Band on July 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for KALV entered a downward trend on June 05, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 07, 2025. You may want to consider a long position or call options on KALV as a result. In of 82 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for KALV just turned positive on July 07, 2025. Looking at past instances where KALV's MACD turned positive, the stock continued to rise in of 38 cases over the following month. The odds of a continued upward trend are .

KALV moved above its 50-day moving average on July 07, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for KALV crossed bullishly above the 50-day moving average on July 09, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where KALV advanced for three days, in of 285 cases, the price rose further within the following month. The odds of a continued upward trend are .

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. KALV’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.605) is normal, around the industry mean (17.368). P/E Ratio (0.000) is within average values for comparable stocks, (59.372). KALV's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.445). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (273.506).

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KALV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
KALV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

KALV is expected to report earnings to fall 9.09% to -89 cents per share on September 04

KalVista Pharmaceuticals KALV Stock Earnings Reports
Q3'25
Est.
$-0.90
Q2'25
Missed
by $0.14
Q1'25
Missed
by $0.05
Q4'24
Beat
by $0.02
Q3'24
Beat
by $0.03
The last earnings report on July 10 showed earnings per share of -99 cents, missing the estimate of -84 cents. With 2.08M shares outstanding, the current market capitalization sits at 725.33M.
A.I. Advisor
published General Information

General Information

a developer of pharmaceuticals

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
55 Cambridge Parkway
Phone
+1 857 999-0075
Employees
118
Web
https://www.kalvista.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
DLQIX15.89N/A
N/A
BNY Mellon Large Cap Equity I
GABIX49.04N/A
N/A
Gabelli Asset I
CFWCX27.04N/A
N/A
Calvert Global Water C
LTFOX20.08N/A
N/A
Lord Abbett Affiliated F3
BPGSX13.87N/A
N/A
Boston Partners Global Sustainablty Ins

KALV and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, KALV has been loosely correlated with ATXS. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KALV jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KALV
1D Price
Change %
KALV100%
-3.00%
ATXS - KALV
47%
Loosely correlated
-1.48%
CRSP - KALV
45%
Loosely correlated
-1.80%
TRDA - KALV
45%
Loosely correlated
-10.70%
IMNM - KALV
42%
Loosely correlated
+0.67%
IDYA - KALV
42%
Loosely correlated
-0.74%
More